Cargando…

Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1

We are developing cytotoxic immunoconjugates (CICs) targeting the envelope protein (Env) of the Human Immunodeficiency Virus, type 1 (HIV) to purge the persistent reservoirs of viral infection. We have previously studied the ability of multiple monoclonal antibodies (mAbs) to deliver CICs to an HIV-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klug, Grant, Cole, Frances M., Hicar, Mark D., Watt, Connie, Peters, Tami, Pincus, Seth H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144985/ https://www.ncbi.nlm.nih.gov/pubmed/37112741 http://dx.doi.org/10.3390/vaccines11040829

Ejemplares similares

Anti-HIV Double Variable Domain Immunoglobulins Binding Both gp41 and gp120 for Targeted Delivery of Immunoconjugates
por: Craig, Ryan B., et al.
Publicado: (2012)

Highly mutated monoclonal antibody 3F2 targets a conformational and strain-restricted epitope in human immunodeficiency virus gp41 with significant antibody-dependent cell cytotoxicity
por: DeCotes, Devin, et al.
Publicado: (2022)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

Identification and Characterization of a Broadly Cross-Reactive HIV-1 Human Monoclonal Antibody That Binds to Both gp120 and gp41
por: Zhang, Mei-Yun, et al.
Publicado: (2012)

Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity
por: Yang, Zheng, et al.
Publicado: (2018)

Muramyl dipeptide CD10 monoclonal antibody immunoconjugates inhibited acute leukemia in nude mice
por: Wang, Yilin, et al.
Publicado: (2023)

IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis
por: Duchemin, Maxence, et al.
Publicado: (2018)

1008. Presence of Antibody Dependent Cell Cytotoxicity (ADCC) Functional Antibodies that Target a Complex Gp41 Epitope Correlates with Long-term Non-progression and ADCC is Maintained with Mutants Using Germline Heavy Chain Variable Gene Sequence of VH1-02 Gene
por: Baron, Sarah, et al.
Publicado: (2021)

Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate.
por: Sivolapenko, G. B., et al.
Publicado: (1991)

641. Development of Structural Epitope Targeting During B-cell Ontogeny by Exploration of Relatives of Gp41 Structural Epitope Binding Antibody 6F5
por: Baron, Sarah, et al.
Publicado: (2018)

Effect of Gelonin Immunoconjugate with Monoclonal Antibody MSN‐1 to Endometrial Adenocarcinoma on Antigen‐producing Tumor Cells in vivo
por: Kaneta, Yoshibumi, et al.
Publicado: (1998)

Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells
por: Khandelwal, Soni, et al.
Publicado: (2018)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

Cytotoxicity of HIV-gp41 segments expressed inE. coli
por: Yuan, Yuhua, et al.
Publicado: (2004)

274. Potential HIV vaccine gp41 epitope targeting antibodies identify peptides with similarity to proposed Kawasaki disease related peptide, suggesting non-specific mimotope targeting of acidic amino acid enriched regions
por: Hakimuddin, Sojar, et al.
Publicado: (2023)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata.
por: Di Massimo, A. M., et al.
Publicado: (1997)

Tumor Localization and in vivo Antitumor Activity of the Immunoconjugate Composed of Anti‐human Colon Cancer Monoclonal Antibody and Mitomycin C‐Dextran Conjugate
por: Noguchi, Akinori, et al.
Publicado: (1991)

Maternal Envelope gp41 Ectodomain-Specific Antibodies Are Associated With Increased Mother-to-Child Transmission of Human Immunodeficiency Virus-1
por: Naiman, Nicole E, et al.
Publicado: (2020)

C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic
por: Steckbeck, Jonathan D., et al.
Publicado: (2013)

Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status
por: Lucar, Olivier, et al.
Publicado: (2017)

Effectiveness of Polyclonal Antibody Immunoconjugate Treatment with Propamidine Isethionate for Amoebic Keratitis in Golden Hamsters
por: Ávila-Blanco, Manuel Enrique, et al.
Publicado: (2023)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome
Publicado: (1988)

Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination
por: Sharma, SK, et al.
Publicado: (2012)

Identification of HIV gp41-specific antibodies that mediate killing of infected cells
por: Williams, Katherine L., et al.
Publicado: (2019)

Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives
por: Mercatelli, Daniele, et al.
Publicado: (2018)

The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41
por: Perween, Reshma, et al.
Publicado: (2021)

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity
por: Rubio, Adonis A., et al.
Publicado: (2021)

Diversification of Specificity after Maturation of the Antibody Response to the HIV gp41 Epitope ELDKWA
por: White, Henry N., et al.
Publicado: (2012)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
por: Verkoczy, Laurent, et al.
Publicado: (2014)

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
por: Huang, Jinghe, et al.
Publicado: (2012)

Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies
por: Caillat, Christophe, et al.
Publicado: (2021)

FHR4‐based immunoconjugates direct complement‐dependent cytotoxicity and phagocytosis towards HER2‐positive cancer cells
por: Seguin‐Devaux, Carole, et al.
Publicado: (2019)

Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes
por: Strokappe, Nika M., et al.
Publicado: (2019)

Structural and Mechanistic Evidence for Calcium Interacting Sites in the HIV Transmembrane Protein gp41 Involved in Membrane Fusion
por: Klug, Yoel A., et al.
Publicado: (2022)

Systematic Analysis of Intracellular Trafficking Motifs Located within the Cytoplasmic Domain of Simian Immunodeficiency Virus Glycoprotein gp41
por: Postler, Thomas S., et al.
Publicado: (2014)

Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.
por: King, D. J., et al.
Publicado: (1995)

Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41
por: Sabin, Charles, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_lggpdooonhs954049le6uhcm00